Technology
Health
Biotechnology

MorphoSys

$23.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.59 (-2.46%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MorphoSys and other stocks, options, ETFs, and crypto commission-free!

About

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. Read More The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Employees
329
Headquarters
Planegg, Bayern (Bavaria)
Founded
1992
Market Cap
3.03B
Price-Earnings Ratio
Dividend Yield
Average Volume
55.86K
High Today
$23.61
Low Today
$23.00
Open Price
$23.02
Volume
20.29K
52 Week High
$35.90
52 Week Low
$21.75

Collections

Technology
Health
Biotechnology
Research And Development
Therapy
Pharmaceutical
2018 IPO
Europe (Non-UK)

News

Markets InsiderMar 19

MorphoSys, I-Mab Biopharma Initiate Phase 2 Study Of TJ202/MOR202 For MM

(RTTNews) - MorphoSys AG (MOR) and I-Mab Biopharma announced that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.

5
Markets InsiderMar 19

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 19, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), today announced that the first patient dosing (FPD) has been achieved in a phase 2 multi-center clinical study in Taiwan to evaluate an investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.

6
Seeking AlphaMar 14

MorphoSys AG's (MOR) CEO Simon Moroney on Q4 2018 Results - Earnings Call Transcript

MorphoSys AG (NASDAQ:MOR) Q4 2018 Results Earnings Conference Call March 14, 2019 5:00 PM ET Company Participants Verena Kupas - Manager, Corporate Communications and Investor Relations Simon Moroney - Chief Executive Officer Jens Holstein - Chief Financial Officer Malte Peters - Chief Development Officer Markus Enzelberger - Chief Scientific Officer Conference Call Participants Brad Canino - SVB Leerink Danielle Brill - Piper Jaffray Anastasia Karpova - Kempen Gunnar Romer - Deutsche Bank Jason...

3

Earnings

-$1.57
-$0.68
$0.20
$1.09
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$1.57 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.